Immunotherapy News and Research

Latest Immunotherapy News and Research

ImmunoVaccine Technologies to acquire Immunotope

ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.

10 Dec 2007

FDA approves trial for SKCC breast cancer vaccine

The Federal Drug Administration announced Friday approval of a Phase 1 clinical trial designed to study a breast cancer vaccine developed at the Sidney Kimmel Cancer Center.

10 Dec 2007

Vaccine improves event-free survival for leukemia patients

Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

10 Dec 2007

Lymphatic vessel and lymph node function are restored with growth factor treatment

The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.

4 Dec 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

Researchers transfer immune response to myeloma patient

Researchers at the University of Arkansas for Medical Sciences (UAMS) have for the first time transferred an immune response in a healthy individual to a patient with multiple myeloma, a cancer of the bone marrow, showing promise for cancer vaccination.

27 Nov 2007

Discovery of new signaling molecule could lead to the development of new treatments for cancer

Investigators at St. Jude Children's Research Hospital have discovered a new signaling molecule that prevents immune responses from running amok and damaging the body.

21 Nov 2007

The immune system can stop the growth of a cancerous tumor without actually killing it

A multinational team of researchers has shown for the first time that the immune system can stop the growth of a cancerous tumor without actually killing it.

19 Nov 2007

New guidelines on non-muscle invasive bladder cancer

The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.

13 Nov 2007

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Antibody might help starve cancerous tumors

An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell, a publication of Cell Press.

2 Nov 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Clinical trial to evaluate glioblastoma multiforme vaccine commences at NYU

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center.

19 Oct 2007

Bacteria reveal targets of immune responses quick and direct identification of antigens

The Epstein-Barr virus (EBV) is a widespread herpes virus that infects more than 90 per cent of the worldwide human population.

10 Oct 2007

Trial results of lovaxin C in advanced cervical cancer patients

A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients.

10 Oct 2007

Study helps determine best treatment for bladder cancer

Cancer specialists and researchers at Princess Margaret Hospital, University Health Network (UHN), are tackling an ongoing controversy about the best way to treat an aggressive form of bladder cancer – immediate radical surgery or a more conservative initial approach using immunotherapy?

25 Sep 2007